Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
Sponsor: Aurinia Pharmaceuticals Inc.
Summary
This clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept.
Official title: A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients With Generalized Myasthenia Gravis
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
81
Start Date
2026-04-22
Completion Date
2029-03-02
Last Updated
2026-08-03
Healthy Volunteers
No
Conditions
Interventions
Aritinercept
For subcutaneous injection
Placebo
For subcutaneous injection
Locations (11)
Aurinia Investigational Site
Pasadena, California, United States
Aurinia Investigational Site
Altamonte Springs, Florida, United States
Aurinia Investigational Site
Boca Raton, Florida, United States
Aurinia Investigational Site
Homestead, Florida, United States
Aurinia Investigational Site
Miami, Florida, United States
Aurinia Investigational Site
Miami, Florida, United States
Aurinia Investigational Site
Chicago, Illinois, United States
Aurinia Investigational Site
O'Fallon, Illinois, United States
Aurinia Investigational Site
Dearborn, Michigan, United States
Aurinia Investigational Site
Flint, Michigan, United States
Aurinia Investigational Site
Houston, Texas, United States